```
=> d his

     (FILE 'HOME' ENTERED AT 12:59:47 ON 05 SEP 2006)

     FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006
L1             STRUCTURE UPLOADED
L2           7 S L1
L3          96 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006
L4          56 S L3
L5           1 S L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)
L6          38 S L3/THU
L7          17 S L6 AND PPAR
L8           3 S L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)
L9           5 S L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

     FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006
               SEL L2
               SEL L3

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006
               SEA CIGLITAZONE AND ASTHMA
              ---------
               1   FILE AGRICOLA
               1   FILE BIOENG
               5   FILE BIOSIS
               1   FILE BIOTECHABS
               1   FILE BIOTECHDS
               1   FILE CABA
              12   FILE CAPLUS
               5   FILE DDFU
               5   FILE DRUGU
              12   FILE EMBASE
               6   FILE ESBIOBASE
               4   FILE IFIPAT
               1   FILE LIFESCI
               7   FILE MEDLINE
               4   FILE PASCAL
               9   FILE SCISEARCH
               1   FILE TOXCENTER
             390   FILE USPATFULL
              62   FILE USPAT2
               5   FILE WPIDS
               1   FILE WPIFV
               5   FILE WPINDEX
              24   FILE EPFULL
             101   FILE IMSPATENTS
               1   FILE INPADOC
               1   FILE PATDPAFULL
             259   FILE PCTFULL
L10             QUE CIGLITAZONE AND ASTHMA
               ---------

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
L11        649 S CIGLITAZONE AND ASTHMA
L12        203 S L11 AND PPAR

     FILE 'EMBASE, CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006
L13         24 S CIGLITAZONE AND ASTHMA
L14         18 S L13 AND PPAR
```

```
L15          14 DUP REM L14 (4 DUPLICATES REMOVED)
L16           0 S L14 NOT PY>2002

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
L17          18 S L12 NOT PY>2002

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006
               SEA (E9-E111) AND ASTHMA
               ---------
               1   FILE CAPLUS
               1   FILE IFIPAT
              21   FILE USPATFULL
               2   FILE USPAT2
               1   FILE WPIDS
               1   FILE WPINDEX
              22   FILE PCTFULL
L18             QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"
               ---------

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006
L19          43 S (E9-E111) AND ASTHMA
L20          14 S L19 NOT PY>2003
```

```
=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 SEP 2006  HIGHEST RN 905816-92-4
DICTIONARY FILE UPDATES:   4 SEP 2006  HIGHEST RN 905816-92-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10674395.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 O,S


Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 13:00:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       57 TO ITERATE

100.0% PROCESSED       57 ITERATIONS                              7 ANSWERS
SEARCH TIME: 00.00.01
```

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 688 TO 1592
PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1

=> d l2 scan

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[2-(2-benzofuranyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C24 H20 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[2-[(3,5-dimethoxyphenoxy)methyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C25 H26 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-(2-phenyl-4-thiazolyl)ethoxy]phenyl]methyl]- (9CI)
MF C21 H18 N2 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-5-(2-naphthalenylsulfonyl)- (9CI)
MF C32 H26 N2 O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[5-methyl-2-[1-(2-pyridinylthio)ethyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C23 H23 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[2-[5-methyl-2-(1-methyl-3-cyclohexen-1-yl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)
MF C23 H26 N2 O4 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 7 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2,4-Thiazolidinedione, 5-[[4-[(2-phenyl-4-thiazolyl)methoxy]phenyl]methyl]- (9CI)
MF C20 H16 N2 O3 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss full
FULL SEARCH INITIATED 13:03:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1125 TO ITERATE

100.0% PROCESSED 1125 ITERATIONS 96 ANSWERS
SEARCH TIME: 00.00.01

```
L3            96 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     169.14     169.35

FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Sep 2006  VOL 145 ISS 11
FILE LAST UPDATED: 4 Sep 2006  (20060904/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            56 L3

=> s l4 and (asthma or allergy or hypersensitivity)
          32098 ASTHMA
          44344 ALLERGY
          20887 HYPERSENSITIVITY
L5             1 L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)

=> d l5 1 ti

L5   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   peroxisome proliferator-activated receptor-α agonist- and
     cyclooxygenase-2 selective inhibitor-containing compositions, and methods
     of treatment using them


=> d l4 1-6 ti

L4   ANSWER 1 OF 56  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Methods and compositions for treating glucose-associated conditions,
     metabolic syndrome, dyslipidemias and other conditions

L4   ANSWER 2 OF 56  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Molecular docking studies on pyridine derivatives of glitazones as
     PPARγ agonists

L4   ANSWER 3 OF 56  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Gene expression profiles for determining whether an agent possesses a
     defined biological activity using efficacy, toxicity, and classifier
     comparisons
```

L4 ANSWER 4 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Therapeutic uses of dunaliella powder

L4 ANSWER 5 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-(5-phosphono)furanyl substituted heteroaromatic compounds as fructose-1,6-bisphosphatase (FBPase) inhibitors for use in combination with insulin sensitizers for the treatment of diabetes

L4 ANSWER 6 OF 56 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones

=> s l3/thu
56 L3
807585 THU/RL
L6 38 L3/THU
(L3 (L) THU/RL)

=> s l6 and PPAR
7940 PPAR
L7 17 L6 AND PPAR

=> s l7 and (asthma or allergy or inflammation)
32098 ASTHMA
44344 ALLERGY
157219 INFLAMMATION
L8 3 L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

=> d l8 1-3 ti

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI peroxisome proliferator-activated receptor-α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo

=> d l8 1-3 ti abs bib

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons
AB In one aspect, the present invention provides methods for determining whether an
agent (e.g., candidate drug) possesses a biol. activity and populations of nucleic acid mols. useful as probes for measuring the level of expression of populations of genes. The methods comprise includes 3 steps. Efficacy values of the agents are compared to at least one reference efficacy value to thield an efficacy comparison result, wherein each efficacy value represents at least one expression pattern of the same efficacy-related population of genes, or at least one expression pattern of the same efficacy-related population of proteins. Toxicity values of the agent are compared to at least one reference toxicity value to yield a toxicity

comparison result based on gene expression in an analogous fashion. Third, a classifier value of the agent is compared to at least one reference classifier value to yield a classifier comparison value. The comparison result(s) obtained from efficacy, toxicity, and classifier values determine whether the agent possesses the defined biol. activity. The method is exemplified by identified gene expression patterns for agonists, or partial agonists, of peroxisome proliferator-activator receptor γ (PPARγ) in mouse and rat models.

AN 2005:348905 CAPLUS
DN 142:385959
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons
IN Lum, Pek Yee; Tan, Yejun; Dai, Hongyue; Muise, Eric Stanley; Berger, Joel P.; Thompson, John R.
PA USA
SO U.S. Pat. Appl. Publ., 51 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005084872	A1	20050421	US 2004-764420	20040123
PRAI	US 2003-442797P	P	20030124		
	US 2003-474413P	P	20030530		

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI peroxisome proliferator-activated receptor-α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them
AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of a cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-α agonist and a cyclooxygenase-2 selective inhibitor (e.g. celecoxib; preparation described), or prodrug thereof. Compns., pharmaceutical compns., and kits for effecting the particular methods are also described.
AN 2003:570750 CAPLUS
DN 139:111706
TI peroxisome proliferator-activated receptor-α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them
IN Needleman, Philip
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003059271	A2	20030724	WO 2003-US1099	20030114
	WO 2003059271	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003220374	A1	20031127	US 2003-341174	20030113
	CA 2472199	AA	20030724	CA 2003-2472199	20030114
	AU 2003207557	A1	20030730	AU 2003-207557	20030114
	AU 2003207557	A2	20030730		
	EP 1465621	A2	20041013	EP 2003-705768	20030114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1642544	A	20050720	CN 2003-805886	20030114
	BR 2003006872	A	20050906	BR 2003-6872	20030114
	JP 2006501136	T2	20060112	JP 2003-559436	20030114
	ZA 2004005562	A	20051004	ZA 2004-5562	20040713
PRAI	US 2002-348298P	P	20020114		
	US 2003-341174	A	20030113		
	WO 2003-US1099	W	20030114		

OS MARPAT 139:111706

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo

AB The authors investigated the potential use of peroxisome proliferator-activated receptor γ (PPARγ) agonists as anti-inflammatory agents in cell-based assays and in a mouse model of endotoxemia. Human peripheral blood monocytes were treated with LPS or PMA and a variety of PPARγ agonists. Although 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) at micromolar concns. inhibited the production of TNF-α and IL-6, 4 other high affinity PPARγ ligands failed to affect cytokine production Similar results were obtained when the monocytes were allowed to differentiate in culture into macrophages that expressed higher levels of PPAR γ or when the murine macrophage cell line RAW 264.7 was used. Furthermore, saturating concns. of a potent PPARγ ligand not only failed to block cytokine production, but also were unable to block the inhibitory activity of 15d-PGJ2. Thus, activation of PPAR γ does not appear to inhibit the production of cytokines by either monocytes or macrophages, and the inhibitory effect observed with 15d-PGJ2 is most likely mediated by a PPARγ-independent mechanism. To examine the anti-inflammatory activity of PPARγ agonists in vivo, db/db mice were treated with a potent thiazolidinedione that lowered their elevated blood glucose and triglyceride levels as expected. When thiazolidinedione-treated mice were challenged with LPS, they displayed no suppression of cytokine production Rather, their blood levels of TNF-α and IL-6 were elevated beyond the levels observed in control db/db mice challenged with LPS. Comparable results were obtained with the corresponding lean mice. Thus, compds. capable of activating PPAR γ in leukocytes will not be useful for the treatment of acute inflammation.

AN 2000:52487 CAPLUS

DN 132:202817

TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo

AU Thieringer, Rolf; Fenyk-Melody, Judy E.; Le Grand, Cheryl B.; Shelton, Beverly A.; Detmers, Patricia A.; Somers, Elizabeth P.; Carbin, Linda; Moller, David E.; Wright, Samuel D.; Berger, Joel

CS Departments of Endocrinology and Chemical Biology, Merck Research Laboratories, Rahway, NJ, 07065, USA

SO Journal of Immunology (2000), 164(2), 1046-1054
CODEN: JOIMA3; ISSN: 0022-1767

PB American Association of Immunologists

DT Journal

LA English

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l6 and (asthma or allergy or inflammation)
32098 ASTHMA
44344 ALLERGY
157219 INFLAMMATION
L9 5 L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

=> d l9 1-5 ti

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Gene expression profiles for determining whether an agent possesses a defined biological activity using efficacy, toxicity, and classifier comparisons

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI peroxisome proliferator-activated receptor-α agonist- and cyclooxygenase-2 selective inhibitor-containing compositions, and methods of treatment using them

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Activation of peroxisome proliferator-activated receptor γ does not inhibit IL-6 or TNF-α responses of macrophages to lipopolysaccharide in vitro or in vivo

=> d l9 1 3 ti abs bib

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
AB The invention relates, in part, to of glutamic acid boroproline (Glu-boroPro) containing compds. and methods of use thereof in the prevention or management of conditions that are associated with impaired glucose tolerance such as diabetes. The invention also relates to compns. of Glu-boroPro containing compds. and methods of use thereof in the prevention or management of conditions such as metabolic syndrome, dyslipidemias, inflammation, cardiovascular disorders such as hypertension and atherosclerosis, and to reduce body weight or prevent weight gain. The compds. of the invention are also useful in lowering levels of triglycerides, free fatty acids, C-reactive protein (CRP), HbA1C, total glycosylated Hb (TGHb), in increasing insulin sensitivity index and in stimulating insulin release. The method may further comprise administering a second agent such as an antidiabetic agent. The inhibition of the serine protease DPP-IV by the compds. in vitro and vivo was determined
AN 2006:295558 CAPLUS
DN 144:343604
TI Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
IN Aziz, Nazneen; Jesson, Michael I.; McLean, Paul, A.; Miller, Glenn T.; Jones, Barry
PA Point Therapeutics, Inc., USA
SO PCT Int. Appl., 148 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034435	A2	20060330	WO 2005-US34112	20050921
	WO 2006034435	A3	20060803		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006094693	A1	20060504	US 2005-233532	20050921
PRAI	US 2004-612069P	P	20040921		
	US 2004-622466P	P	20041027		
	US 2005-700871P	P	20050719		
	US 2005-704157P	P	20050729		

OS MARPAT 144:343604

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones
AB The invention provides methods for treatment and/or prevention of diabetes and diabetes-related diseases. More specifically, the methods and uses of the invention pertains to administration of an exendin-4 compound in combination with administration of a thiazolidinedione insulin sensitizer.
AN 2004:490736 CAPLUS
DN 141:47336
TI Combination treatment for diabetes and related diseases using exendins and thiazolidinediones
IN Knudsen, Lotte Bjerre
PA Novo Nordisk A/S, Den.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004050115	A2	20040617	WO 2003-DK824	20031201
	WO 2004050115	A3	20040722		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003283216	A1	20040623	AU 2003-283216	20031201
	EP 1569682	A2	20050907	EP 2003-775117	20031201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	EP 1688148	A1	20060809	EP 2006-112986	20031201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

```
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK
     US 2004180824        A1    20040916    US 2003-726734          20031203
     US 2006189535        A1    20060824    US 2006-414114          20060428
PRAI DK 2002-1864         A     20021203
     US 2002-431999P      P     20021209
     EP 2003-775117       A3    20031201
     WO 2003-DK824        W     20031201
     US 2003-726734       B1    20031203


=> sel l2
NO ANSWERS SELECTED.  THE ANSWER SET WAS CREATED IN FILE 'REGISTRY'.
USE THE FILE COMMAND TO CHANGE TO THE CORRECT FILE.
An answer set can be processed to create terms only
in the same file in which it was created.

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      43.78     213.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -3.75      -3.75

FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     4 SEP 2006  HIGHEST RN 905816-92-4
DICTIONARY FILE UPDATES:    4 SEP 2006  HIGHEST RN 905816-92-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=> sel l2
E1 THROUGH E8 ASSIGNED

=> sel l3
E9 THROUGH E111 ASSIGNED

=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      34.43     247.56

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
```

```
                                                          ENTRY    SESSION
CA SUBSCRIBER PRICE                                        0.00      -3.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s ciglitazone and asthma
          1   FILE AGRICOLA
          1   FILE BIOENG
          5   FILE BIOSIS
          1   FILE BIOTECHABS
          1   FILE BIOTECHDS
          1   FILE CABA
         12   FILE CAPLUS
          5   FILE DDFU
          5   FILE DRUGU
         12   FILE EMBASE
          6   FILE ESBIOBASE
          4   FILE IFIPAT
          1   FILE LIFESCI
          7   FILE MEDLINE
  45 FILES SEARCHED...
          4   FILE PASCAL
          9   FILE SCISEARCH
          1   FILE TOXCENTER
        390   FILE USPATFULL
         62   FILE USPAT2
          5   FILE WPIDS
          1   FILE WPIFV
          5   FILE WPINDEX
         24   FILE EPFULL
        101   FILE IMSPATENTS
          1   FILE INPADOC
  78 FILES SEARCHED...
          1   FILE PATDPAFULL
        259   FILE PCTFULL

  27 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L10  QUE CIGLITAZONE AND ASTHMA

=> file uspatfull pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     1.83     249.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.75

FILE 'USPATFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
COPYRIGHT (C) 2006 Univentio

=> s ciglitazone and asthma
```

```
L11         649 CIGLITAZONE AND ASTHMA

=> s l11 and PPAR
L12         203 L11 AND PPAR

=> d l12 1-1o ti
'1-1O' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files.  Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):ti

L12  ANSWER 1 OF 203  USPATFULL on STN
TI     Thiazole and thiadiazole inhibitors of tyrosine phosphatases


=> d l12 1-10 ti

L12  ANSWER 1 OF 203  USPATFULL on STN
TI     Thiazole and thiadiazole inhibitors of tyrosine phosphatases

L12  ANSWER 2 OF 203  USPATFULL on STN
TI     Albumin fusion proteins

L12  ANSWER 3 OF 203  USPATFULL on STN
TI     Protein HDPBQ71

L12  ANSWER 4 OF 203  USPATFULL on STN
TI     Treatment of immune-mediated disorders with active vitamin D compounds
       alone or in combination with other therapeutic agents

L12  ANSWER 5 OF 203  USPATFULL on STN
TI     Novel piperazines

L12  ANSWER 6 OF 203  USPATFULL on STN
TI     Modulators of FAAH

L12  ANSWER 7 OF 203  USPATFULL on STN
TI     Methods for modulating PPAR biological activity for the
       treatment of diseases caused by mutations in the CFTR gene

L12  ANSWER 8 OF 203  USPATFULL on STN
TI     Methods of treating and diagnosing diabetes with cx3cr1 modulators

L12  ANSWER 9 OF 203  USPATFULL on STN
TI     Novel therapeutic method and compositions for topical administration

L12  ANSWER 10 OF 203  USPATFULL on STN
TI     Novel therapeutic method and compositions for topical administration


=> file embase caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               2.94     252.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00      -3.75

FILE 'EMBASE' ENTERED AT 13:11:28 ON 05 SEP 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.
```

```
FILE 'CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ciglitazone and asthma
L13          24 CIGLITAZONE AND ASTHMA

=> s l13 and ppar
L14          18 L13 AND PPAR

=> dup rem l14
PROCESSING COMPLETED FOR L14
L15          14 DUP REM L14 (4 DUPLICATES REMOVED)

=> s l14 not py>2002
L16           0 L14 NOT PY>2002

=> file uspatfull pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     9.69     262.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.75

FILE 'USPATFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
COPYRIGHT (C) 2006 Univentio

=> s l12 not py>2002
L17          18 L12 NOT PY>2002

=> d l17 1-18 ti

L17  ANSWER 1 OF 18  USPATFULL on STN
TI     Substituted imidazoles, their preparation and use

L17  ANSWER 2 OF 18  USPATFULL on STN
TI     Modulators of protein tyrosine phosphateses (PTPases)

L17  ANSWER 3 OF 18  USPATFULL on STN
TI     Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

L17  ANSWER 4 OF 18  USPATFULL on STN
TI     Imidazole compounds

L17  ANSWER 5 OF 18  USPATFULL on STN
TI     Pharmaceutical compositions of glycogen phosphorylase inhibitors

L17  ANSWER 6 OF 18  USPATFULL on STN
TI     Compositions and methods for the treatment of Alzheimer's disease,
       central nervous system injury, and inflammatory diseases

L17    ANSWER 7 OF 18    PCTFULL   COPYRIGHT 2006 Univentio on STN
TIEN   ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED
       USES
TIFR   COMPOSES D'ETHER ET COMPOSITIONS POUR LA GESTION DU CHOLESTEROL ET
       UTILISATIONS ASSOCIEES

L17    ANSWER 8 OF 18    PCTFULL   COPYRIGHT 2006 Univentio on STN
```

TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES

L17 ANSWER 9 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3

L17 ANSWER 10 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE

L17 ANSWER 11 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L17 ANSWER 12 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES
TIFR ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

L17 ANSWER 13 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
TIFR MODULATEURS DE PROTEINES TYROSINE PHOSPHATAGES (PTPases)

L17 ANSWER 14 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
TIFR MODULATEURS DE PROTEINE TYROSINE PHOSPHATASE (PTPases)

L17 ANSWER 15 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PIPERIDYL-IMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THERAPEUTIC USES
TIFR DERIVES DE PIPERIDYLE-IMIDAZOLE, PREPARATIONS DANS LESQUELLES ILS
      ENTRENT ET UTILISATIONS THERAPEUTIQUES DE CES DERNIERES

L17 ANSWER 16 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION

L17 ANSWER 17 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION

L17 ANSWER 18 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
      CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
      LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES

=> d l17 1 2 4 6 8 9 10 16 17 18 ti abs bib

L17 ANSWER 1 OF 18 USPATFULL on STN
TI Substituted imidazoles, their preparation and use
AB A class of substituted imidazole compounds of formula I ##STR1##

    methods for their preparation, pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to the histamine H3 receptor are disclosed. More particularly, these compounds possess histamine H3 receptor antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3 receptor blockade is beneficial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:168250 USPATFULL
TI Substituted imidazoles, their preparation and use
IN Dorwald, Florencio Zaragoza, Ballerup, DENMARK

Andersen, Knud Erik, Br.o slashed.ndby, DENMARK
PA Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)
Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)
PI US 6417218 B1 20020709
AI US 2000-484621 20000118 (9)
PRAI DK 1999-54 19990118
US 1999-116510P 19990120 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Higel, Floyd D.; Assistant Examiner: Sackey, Ebenezer
LREP Green, Esq., Reza, Waibel, Esq., Peter J.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1747
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 2 OF 18 USPATFULL on STN
TI Modulators of protein tyrosine phosphateses (PTPases)
AB Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) including PTP1B, T cell PTP, ##STR1##

wherein n, m, X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, and R.sub.7 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:152652 USPATFULL
TI Modulators of protein tyrosine phosphateses (PTPases)
IN Andersen, Henrik Sune, Lyngby, DENMARK
Hansen, Thomas Kruse, Herlev, DENMARK
Lau, Jesper, Farum, DENMARK
M.o slashed.ller, Niels Peter Hundahl, K.o slashed.benhavn .O slashed., DENMARK
Olsen, Ole Hvilsted, Br.o slashed.nsh.o slashed.j, DENMARK
Axe, Frank Urban, Escondido, CA, United States
Ge, Yu, San Diego, CA, United States
Holsworth, Daniel Dale, San Diego, CA, United States
Jones, Todd Kevin, Solana Beach, CA, United States
Judge, Luke Milburn, Seattle, WA, United States
Ripka, Wiliam Charles, San Diego, CA, United States
Shapira, Barry Zvi, Acton, CA, United States
Uyeda, Roy Teruyuki, San Diego, CA, United States
PA Novo Nordisk A/S, Bagsvaerd, DENMARK (non-U.S. corporation)
Ontogen Corporation, Carlsbad, CA, United States (U.S. corporation)
PI US 6410556 B1 20020625
AI US 2000-659547 20000911 (9)
PRAI DK 1999-1277 19990910
DK 2000-1069 20000707
US 1999-156742P 19990930 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Dentz, Bernard
LREP Green, Esq., Reza, Waibel, Esq., Peter J.
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 5739
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 4 OF 18 USPATFULL on STN
TI Imidazole compounds
AB A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:112918 USPATFULL
TI Imidazole compounds
IN Andersen, Knud Erik, Brondby, DENMARK
Dorwald, Florencio Zaragiza, Ballerup, DENMARK
Peschke, Bernd, Malov, DENMARK
Sidelmann, Ulla Grove, Valby, DENMARK
Rudolf, Klaus, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Stenkamp, Dirk, Biberach, GERMANY, FEDERAL REPUBLIC OF
Hurnaus, Rudolf, Biberach, GERMANY, FEDERAL REPUBLIC OF
Muller, Stephan Georg, Warthausen, GERMANY, FEDERAL REPUBLIC OF
Krist, Bernd, Ulm, GERMANY, FEDERAL REPUBLIC OF
Eriksen, Birgitte, Farum, GERMANY, FEDERAL REPUBLIC OF
PI US 2002058659 A1 20020516
US 6437147 B2 20020820
AI US 2001-810237 A1 20010316 (9)
PRAI DK 2000-441 20000317
DK 2000-1016 20000629
US 2000-193741P 20000331 (60)
US 2000-216553P 20000707 (60)
DT Utility
FS APPLICATION
LREP Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., Suite 6400, 405 Lexington Avenue, New York, NY, 10174-6401
CLMN Number of Claims: 42
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 6 OF 18 USPATFULL on STN
TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AB The present invention relates to methods and compositions for treating Alzheimer's disease and other diseases and conditions with an inflammatory component (e.g., central nervous system injury). In particular, the present invention provides agents that regulate the production of proinflammatory and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:25919 USPATFULL
TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
IN Landreth, Gary, Shaker Heights, OH, United States
Combs, Colin, University Heights, OH, United States
Silver, Jerry, Bay Village, OH, United States
Fitch, Michael T., S. Euclid, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6191154 B1 20010220
AI US 1998-200700 19981127 (9)
DT Utility
FS Granted

EXNAM Primary Examiner: Criares, Theodore J.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 8 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
ABEN The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatological, cardiovascular immunological, neurological, ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, and a PPARγ agonist which cross-activates PPARα or PPARδ or both, or a PPARγ partial agonist, or a PPAR γ/RXR agonist, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.
ABFR L'invention concerne des procedes d'utilisation de ligands PPAR dans le traitement de maladies inflammatoires endocrines, dermatologiques, cardio-vasculaires, immunologiques, neurologiques, ophtalmiques, neoplasiques, pulmonaires, et de dysfonctionnements lies a l'age. L'invention concerne de plus des methodes de traitement de ces etats et maladies, qui comprennent l'etape consistant a administrer a un etre humain ou a un animal necessitant un tel traitement une quantite therapeutique de compositions pharmacologiques contenant un excipient pharmaceutiquement acceptable et un agoniste de PPARγ qui active par reaction croisee PPARα et/ou PPAR δ, ou un agoniste partiel de PPARγ, ou un agoniste de PPARγ/RXR permettant d'inverser, de ralentir, d'arreter ou de prevenir le processus inflammatoire ou degeneratif.
AN 2002013812 PCTFULL ED 20020711 EW 200208
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
IN PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
PA PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
LAF English
LA English
DT Patent
PI WO 2002013812 A1 20020221
DS W: AU CA MX NZ US
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
AI WO 2001-US25668 A 20010816
PRAI US 2000-60/225,907 20000817
US 2000-60/230,509 20000906

L17 ANSWER 9 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3
ABEN A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
ABFR L'invention concerne une nouvelle classe de composes heterocycliques d'imidazo, des compositions pharmaceutiques renfermant ces composes et

leur utilisation dans le traitement et/ou la prevention de maladies et troubles lies au recepteur d'histamine H3. Plus specifiquement, les composes sont utilises pour le traitement et/ou la prevention de maladies et troubles, dans lesquels une interaction avec le recepteur d'histamine H3 s'avere benefique.

AN 2001068652 PCTFULL ED 20020822
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES EN TANT QUE LIGANDS DE RECEPTEUR D'HISTAMINE H3
IN ANDERSEN, Knud, Erik;
DOeRWALD, Florencio, Zaragoza;
SIDELMANN, Ulla, Grove;
RUDOLF, Klaus;
STENKAMP, Dirk;
HURNAUS, Rudolf;
MUeLLER, Stephan, Georg;
KRIST, Bernd;
ERIKSEN, Birgitte;
PESCHE, Bernd
PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DT Patent
PI WO 2001068652 A1 20010920
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA
UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
NE SN TD TG
AI WO 2001-DK188 A 20010316
PRAI DK 2000-PA 2000 00441 20000317
DK 2000-PA 2000 01016 20000629

L17 ANSWER 10 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE
ABEN A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.
ABFR L'invention concerne une classe de composes heterocycliques imidazo, des compositions pharmaceutiques les comprenant et leur utilisation dans le traitement et/ou la prevention de maladies et de troubles associes au recepteur H3 de l'histamine. En particulier, ces composes sont utiles pour le traitement et/ou la prevention de maladies et de troubles dans lesquels une interaction avec le recepteur H3 de l'histamine est benefique.
AN 2001068651 PCTFULL ED 20020822
TIEN CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS
TIFR IMIDAZOLES CONDENSES COMME LIGANDS DU RECEPTEUR H3 DE L'HISTAMINE
IN ANDERSEN, Knud, Erik;
DOeRWALD, Florencio, Zaragoza;
PESCHKE, Bernd
PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
DT Patent
PI WO 2001068651 A1 20010920
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP
KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX
MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA

UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM
AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR
IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR
NE SN TD TG

AI WO 2001-DK187 A 20010316
PRAI DK 2000-PA 2000 00442 20000317

L17 ANSWER 16 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
ABEN A novel class of substituted imidazole compounds (I), pharmaceutical compositions comprising
them and use thereof in the treatment and/or prevention of diseases and disorders related to the
histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or
prevention of diseases and disorders, in which an interaction with the histamine H3 receptor is
beneficial.
ABFR L'invention concerne une nouvelle classe de composes imidazoles substitues (I), des
compositions pharmaceutiques contenant ces composes, ainsi que l'utilisation de ceux-ci dans le
traitement et/ou la prevention de maladies et troubles associes au recepteur H3 de l'histamine. Ces
composes sont notamment utiles dans le traitement et/ou la prevention de maladies et troubles, dans
lesquels une interaction avec le recepteur H3 de l'histamine est benefique.
AN 2000063208 PCTFULL ED 20020515
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
IN DoeRWALD, Florencio, Zaragoza;
ANDERSEN, Knud, Erik;
JORGENSEN, Tine, Krogh;
PESCHKE, Bernd;
WULFF, Birgitte, Schjellerup;
PETTERSSON, Ingrid;
RUDOLF, Klaus;
STENKAMP, Dirk;
HURNAUS, Rudolf;
MueLLER, Stephan, Georg;
KRIST, Bernd
PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL, GMBH
LA English
DT Patent
PI WO 2000063208 A1 20001026
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE
DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE
KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO
NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ
VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG
KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU
MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
AI WO 2000-DK179 A 20000413
PRAI DK 1999-PA 1999 00508 19990416
DK 1999-PA 1999 01345 19990922
DK 2000-PA 2000 00042 20000112

L17 ANSWER 17 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE
TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION
ABEN A novel class of substituted imidazole derivatives, methods for their

preparation,
pharmaceutical compositions comprising them and use thereof in the treatment of disorders related to
the histamine H3 receptor. More particularly, the compounds possess histamine H3 receptor
antagonistic activity and are thus useful for the treatment of disorders in which a histamine H3
receptor blockade is beneficial. The compounds have general formula (I).

ABFR L'invention concerne une nouvelle classe de derives d'imidazole substitues, leurs procedes de
preparation, des compositions pharmaceutiques les renfermant et leur utilisation dans le traitement
de troubles se rapportant au recepteur H3 de l'histamine. Plus precisement, les composes, qui
presentent une activite antagoniste du recepteur H3 de l'histamine, sont par consequent utiles au
traitement de troubles dans lesquels un blocage du recepteur H3 de l'histamine est benefique. Les
composes presentent la formule generale (I).

AN 2000042023 PCTFULL ED 20020515

TIEN SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE

TIFR IMIDAZOLES SUBSTITUES, LEUR PREPARATION ET UTILISATION

IN ANDERSEN, Knud, Erik;
DoeRWALD, Florencio, Zaragoza

PA NOVO NORDISK A/S;
BOEHRINGER INGELHEIM INTERNATIONAL, GMBH;
ANDERSEN, Knud, Erik;
DoeRWALD, Florencio, Zaragoza

LA English

DT Patent

PI WO 2000042023 A1 20000720

DS W: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK
DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP
KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL
PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN
YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ
MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC
NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AI WO 2000-DK10 A 20000112

PRAI DK 1999-PA 1999 00054 19990118
US 1999-60/116,510 19990120

L17 ANSWER 18 OF 18 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES

TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES

ABEN The present invention relates to methods and compositions for treating Alzheimer's disease and
other diseases and conditions with an inflammatory component (e.g., central nervous system injury).
In particular, the present invention provides agents that regulate the production of proinflammatory
and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an
inflammatory component.

ABFR La presente invention concerne des methodes et des compositions de traitement de la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante inflammatoire (par exemple, des
lesions au systeme nerveux central). En particulier, la presente invention concerne des agents
regulant la production de produits pro-inflammatoires et neurotoxiques appliques dans la maladie

```
       d'Alzheimer ainsi que d'autres maladies et etats a composante
       inflammatoire.
AN     2000032190 PCTFULL  ED 20020515
TIEN   COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,
       CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR   COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE
       LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
IN     LANDRETH, Gary;
       COMBS, Colin;
       SILVER, Jerry;
       FITCH, Michael, T.
PA     CASE WESTERN RESERVE UNIVERSITY
LA     English
DT     Patent
PI     WO 2000032190        A1 20000608
DS     W:            AU CA IL JP KR AT BE CH CY DE DK ES FI FR GB GR IE IT LU
                     MC NL PT SE
AI     WO 1999-US27987      A  19991124
PRAI   US 1998-09/200,700       19981127


=> index bioscience patents
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ENCOMPPAT2' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    20.49     282.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -3.75

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
       AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
       CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
       DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (E9-E111) and asthma
          1   FILE CAPLUS
  16 FILES SEARCHED...
  29 FILES SEARCHED...
          1   FILE IFIPAT
  38 FILES SEARCHED...
  51 FILES SEARCHED...
         21   FILE USPATFULL
          2   FILE USPAT2
          1   FILE WPIDS
  66 FILES SEARCHED...
          1   FILE WPINDEX
  68 FILES SEARCHED...
  78 FILES SEARCHED...
  86 FILES SEARCHED...
         22   FILE PCTFULL

   7 FILES HAVE ONE OR MORE ANSWERS,   92 FILES SEARCHED IN STNINDEX

L18  QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"/BI OR "BM
         131246"/BI OR "TZD 2"/BI OR "TZD 300512"/BI OR 103787-85-5/BI OR 10378
         7-86-6/BI OR 103787-87-7/BI OR 103787-88-8/BI OR 103787-89-9/BI OR 103
```

787-90-2/BI OR 103787-91-3/BI OR 103787-92-4/BI OR 103787-93-5/BI OR 1
03787-94-6/BI OR 103787-95-7/BI OR 103787-96-8/BI OR 103787-97-9/BI OR
103787-98-0/BI OR 103787-99-1/BI OR 103788-00-7/BI OR 103788-01-8/BI
OR 103788-02-9/BI OR 103788-03-0/BI OR 103788-04-1/BI OR 103788-05-2/B
I OR 103788-06-3/BI OR 103788-07-4/BI OR 103788-08-5/BI OR 103788-09-6
/BI OR 103788-10-9/BI OR 103788-11-0/BI OR 103788-12-1/BI OR 103788-13
-2/BI OR 103788-14-3/BI OR 103788-15-4/BI OR 103788-16-5/BI OR 103788-
17-6/BI OR 103788-18-7/BI OR 103788-19-8/BI OR 103788-20-1/BI OR 10378
8-21-2/BI OR 103788-22-3/BI OR 103788-23-4/BI OR 103788-24-5/BI OR 103
788-25-6/BI OR 103788-26-7/BI OR 103788-27-8/BI OR 103788-28-9/BI OR 1
03788-29-0/BI OR 103788-30-3/BI OR 103788-31-4/BI OR 103788-32-5/BI OR
103788-33-6/BI OR 103788-34-7/BI OR 103788-58-5/BI OR 103814-32-0/BI
OR 103814-33-1/BI OR 103926-56-3/BI OR 141399-27-1/BI OR 141399-28-2/B
I OR 141399-29-3/BI OR 155721-78-1/BI OR 155721-79-2/BI OR 155721-80-5
/BI OR 155721-81-6/BI OR 155721-82-7/BI OR 155721-83-8/BI OR 155721-84
-9/BI OR 155721-85-0/BI OR 155721-86-1/BI OR 155721-87-2/BI OR 155721-
88-3/BI OR 155721-89-4/BI OR 155721-90-7/BI OR 155721-91-8/BI OR 15572
1-92-9/BI OR 155721-93-0/BI OR 155721-94-1/BI OR 155721-95-2/BI OR 155
721-96-3/BI OR 155721-97-4/BI OR 155721-98-5/BI OR 155721-99-6/BI OR 1
55722-00-2/BI OR 155722-01-3/BI OR 171269-88-8/BI OR 171269-89-9/BI OR
171269-90-2/BI OR 171269-91-3/BI OR 171269-92-4/BI OR 171269-93-5/BI
OR 171269-94-6/BI OR 171269-95-7/BI OR 171269-96-8/BI OR 171270-11-4/B
I OR 171270-12-5/BI OR 186894-41-7/BI OR 500718-69-4/BI OR 500718-73-0
/BI OR 746578-79-0/BI)) AND ASTHMA

=> file uspatfull pctfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.27	286.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.75

FILE 'USPATFULL' ENTERED AT 13:18:11 ON 05 SEP 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006
COPYRIGHT (C) 2006 Univentio

=> s (E9-E111) and asthma
L19 43 (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"/BI
OR "BM 131246"/BI OR "TZD 2"/BI OR "TZD 300512"/BI OR 103787-85-
5/BI OR 103787-86-6/BI OR 103787-87-7/BI OR 103787-88-8/BI OR
103787-89-9/BI OR 103787-90-2/BI OR 103787-91-3/BI OR 103787-92-4
/BI OR 103787-93-5/BI OR 103787-94-6/BI OR 103787-95-7/BI OR
103787-96-8/BI OR 103787-97-9/BI OR 103787-98-0/BI OR 103787-99-1
/BI OR 103788-00-7/BI OR 103788-01-8/BI OR 103788-02-9/BI OR
103788-03-0/BI OR 103788-04-1/BI OR 103788-05-2/BI OR 103788-06-3
/BI OR 103788-07-4/BI OR 103788-08-5/BI OR 103788-09-6/BI OR
103788-10-9/BI OR 103788-11-0/BI OR 103788-12-1/BI OR 103788-13-2
/BI OR 103788-14-3/BI OR 103788-15-4/BI OR 103788-16-5/BI OR
103788-17-6/BI OR 103788-18-7/BI OR 103788-19-8/BI OR 103788-20-1
/BI OR 103788-21-2/BI OR 103788-22-3/BI OR 103788-23-4/BI OR
103788-24-5/BI OR 103788-25-6/BI OR 103788-26-7/BI OR 103788-27-8
/BI OR 103788-28-9/BI OR 103788-29-0/BI OR 103788-30-3/BI OR
103788-31-4/BI OR 103788-32-5/BI OR 103788-3

=> s l43 not py>2003
L43 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l19 not py>2003

L20 14 L19 NOT PY>2003

=> d l20 1-14 ti

L20 ANSWER 1 OF 14 USPATFULL on STN
TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses

L20 ANSWER 2 OF 14 USPATFULL on STN
TI Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses

L20 ANSWER 3 OF 14 USPATFULL on STN
TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors

L20 ANSWER 4 OF 14 USPATFULL on STN
TI Methods for identifying novel multimeric agents that modulate receptors

L20 ANSWER 5 OF 14 USPATFULL on STN
TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

L20 ANSWER 6 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 7 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
TIFR MIMIQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 8 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS
TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS SELECTIFS DE LA CYCLOOXYGENASE 2.

L20 ANSWER 9 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS
TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP

L20 ANSWER 10 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
TIFR CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISES POUR PPAR

L20 ANSWER 11 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES
TIFR COMPOSES D'ETHER ET COMPOSITIONS POUR LA GESTION DU CHOLESTEROL ET UTILISATIONS ASSOCIEES

L20 ANSWER 12 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES

L20 ANSWER 13 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES

L20 ANSWER 14 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS
TIFR TECHNIQUE D'IDENTIFICATION DE NOUVEAUX AGENTS MULTIMERES MODULANT DES RECEPTEURS

=> d l20 1 2 3 5 6 7 8 9 10 12 13 ti abs bib

L20 ANSWER 1 OF 14 USPATFULL on STN
TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
AB The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:335335 USPATFULL
TI Mimics of acyl coenzyme-A comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses
IN Dasseux, Jean-Louis, Ann Arbor, MI, UNITED STATES
Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
PI US 2003236213 A1 20031225
AI US 2003-410444 A1 20030410 (10)
PRAI US 2002-371511P 20020410 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 14 USPATFULL on STN
TI Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
AB The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition

comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:335334 USPATFULL
TI Functionalized long chain derivatives as acyl coenzyme-A mimics, compositions thereof, and methods of cholesterol management and related uses
IN Dasseux, Jean-Louis, Ann Arbor, MI, UNITED STATES
Oniciu, Carmen Daniela, Ann Arbor, MI, UNITED STATES
PI US 2003236212 A1 20031225
AI US 2003-410262 A1 20030410 (10)
PRAI US 2002-371511P 20020410 (60)
DT Utility
FS APPLICATION
LREP PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN 8 Drawing Page(s)
LN.CNT 4849
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 14 USPATFULL on STN
TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
AB Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-γ agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:312769 USPATFULL
TI Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
IN Needleman, Philip, Creve Coeur, MO, UNITED STATES
PA Pharmacia Corporation, St. Louis, MO (U.S. corporation)
PI US 2003220374 A1 20031127
AI US 2003-341174 A1 20030113 (10)
PRAI US 2002-348298P 20020114 (60)
DT Utility
FS APPLICATION
LREP Charles E. Dunlap, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC, 29201
CLMN Number of Claims: 56
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4261
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 14 USPATFULL on STN
TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
AB The present invention relates to methods and compositions for treating Alzheimer's disease and other diseases and conditions with an inflammatory component (e.g., central nervous system injury). In particular, the present invention provides agents that regulate the production of proinflammatory and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an inflammatory component.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:25919 USPATFULL
TI Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
IN Landreth, Gary, Shaker Heights, OH, United States
Combs, Colin, University Heights, OH, United States
Silver, Jerry, Bay Village, OH, United States
Fitch, Michael T., S. Euclid, OH, United States
PA Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)
PI US 6191154 B1 20010220
AI US 1998-200700 19981127 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 38 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 3048
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES
TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES
ABEN The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.
ABFR L'invention concerne de nouveaux mimiques d'acyl-coenzyme A, des compositions contenant des composes cetone et des methodes utilisees pour traiter et prevenir les maladies cardio-vasculaires, les dyslipidemies, les dysproteinemies et les troubles du metabolisme du glucose. Ladite invention consiste a administrer une composition contenant un compose cetone. Les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont egalement utiles pour traiter et prevenir la maladie d'Alzheimer, le syndrome X, les troubles lies au recepteur active par le proliferateur de peroxisome, la septicemie, les troubles thrombotiques, l'obesite, la pancreatite, l'hypertension, la nephropathie, le cancer, l'inflammation, les

infections bacteriennes et l'impuissance. Dans certains modes de realisation, les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont utiles en polytherapie avec d'autres agents therapeutiques, tels que les agents hypocholesterolemiants et hypoglycemiants.

AN 2003087108 PCTFULL ED 20031031 EW 200343

TIEN FUNCTIONALIZED LONG CHAIN DERIVATIVES AS ACYL COENZYME-A MIMICS, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR DERIVES FONCTIONNALISES A CHAINE LONGUE UTILISES COMME MIMIQUES D'ACYL-COENZYME A ET LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

IN DASSEUX, Jean-Louis, 7898 Huron Oak Drive, Brighton, MI 48116, US; ONICIU, Carmen, Daniela, 125 Lake Village Drive, Ann Arbor, MI 48103, US

PA ESPERION THERAPEUTICS, INC., 3261 South State Street, 695 KMS Place, Ann Arbor, MI 48101, US [US, US]

AG INSOGNA, Anthony, M., Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US

LAF English

LA English

DT Patent

PI WO 2003087108 A2 20031023

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-US11467 A 20030410

PRAI US 2002-60/371,511 20020410

L20 ANSWER 7 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR MIMIQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

ABEN The invention relates to novel Acyl coenzyme-A mimics, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyshpidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The Acyl coenzyme-A mimics, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, bacterial infection and impotence. In certain embodiments, the Acyl coenzyme-A mimics, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

ABFR L'invention concerne de nouveaux mimiques d'acyl-coenzyme A, des compositions contenant des composes cetone et des methodes utilisees pour traiter et prevenir les maladies cardio-vasculaires, les dyslipidemies, les dysproteinemies et les troubles du metabolisme du glucose. Ladite invention consiste a administrer une composition contenant un compose cetone. Les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont egalement utiles pour traiter et prevenir la maladie d'Alzheimer, le syndrome X, les troubles lies au recepteur active par le proliferateur de peroxisome, la

septicemie, les troubles thrombotiques, l'obesite, la pancreatite, l'hypertension, la nephropathie, le cancer, l'inflammation, les infections bacteriennes et l'impuissance. Dans certains modes de realisation, les mimiques d'acyl-coenzyme A, les compositions, et les methodes de l'invention sont utiles en polytherapie avec d'autres agents therapeutiques, tels que les agents hypocholesterolemiants et hypoglycemiants. .

AN 2003087040 PCTFULL ED 20031031 EW 200343

TIEN MIMICS OF ACYL COENZYME-A COMPRISING PANTOLACTONE AND PANTOTHENIC ACID DERIVATIVES, COMPOSITIONS THEREOF, AND METHODS OF CHOLESTEROL MANAGEMENT AND RELATED USES

TIFR MIMIQUES D'ACYL-COENZYME A COMPRENANT DES DERIVES DE PANTOLACTONE ET D'ACIDE PANTOTHENIQUE, LEURS COMPOSITIONS, METHODES DE REGULATION DU TAUX DE CHOLESTEROL ET UTILISATIONS ASSOCIEES

IN DASSEUX, Jean-Louis, 7898 Huron Oak Drive, Brighton, MI 48116, US; ONICIU, Carmen, Daniela, 125 Lake Village Drive, Ann Arbor, MI 48103, US

PA ESPERION THERAPEUTICS, INC., 3621 South State Street, 695 KMS Place, Ann Arbor, MI 48101, US [US, US]

AG INSOGNA, Anthony, M., Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036, US

LAF English

LA English

DT Patent

PI WO 2003087040 A2 20031023

DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

RW (EAPO): AM AZ BY KG KZ MD RU TJ TM

RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AI WO 2003-US11468 A 20030410

PRAI US 2002-60/371,511 20020410

L20 ANSWER 8 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN

TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS

TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS SELECTIFS DE LA CYCLOOXYGENASE 2.

ABEN Methods for the treatment, prevention, or inhibition of pain, inflammation, or inflammation-related disorder, and for the treatment or inhibition of cardiovascular disease or disorder, and for the treatment or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, include treating the subject with a peroxisome proliferator activated receptor-γ agonist and a cyclooxygenase-2 selective inhibitor or prodrug thereof. Compositions, pharmaceutical compositions and kits for effecting the particular methods are also described.

ABFR La presente invention concerne des procedes de traitement, prevention ou inhibition de la douleur, de l'inflammation, ou des troubles lies a l'inflammation et des procedes de traitement ou inhibition de maladies ou troubles cardio-vasculaires, ainsi que des procedes de traitement ou d'inhibition du cancer chez un sujet necessitant ce type de traitement, prevention ou inhibition. Ces procedes consistent a traiter le sujet a l'aide d'un agoniste γ du recepteur active du proliferateur du peroxysome, et d'un inhibiteur selectif de la cyclooxygenase-2 ou du promedicament de ce dernier. L'invention traite egalement de compositions, compositions pharmaceutiques et de kits pour mettre en oeuvre ces procedes.

AN 2003059271 PCTFULL ED 20030731 EW 200330
TIEN COMPOSITIONS AND METHODS OF TREATMENT INVOLVING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS
TIFR COMPOSITIONS ET PROCEDES DE TRAITEMENT COMPRENANT DES AGONISTES GAMMA DU RECEPTEUR ACTIVE DU PROLIFERATEUR DU PEROXYSOME ET DES INHIBITEURS SELECTIFS DE LA CYCLOOXYGENASE 2.
IN NEEDLEMAN, Philip, 326 New Salem Drive, Creve Coeur, MO 63141, US [US, US]
PA PHARMACIA CORPORATION, Mail Zone MC5S, 575 Maryville Centre Drive, St. Louis, MO 63141, US [US, US], for all designates States except US; NEEDLEMAN, Philip, 326 New Salem Drive, Creve Coeur, MO 63141, US [US, US], for US only
AG DUNLAP, Charles, E., Nelson Mullins Riley & Scarborough, Keenan Building, Third Floor, 1330 Lady Street, Columbia, SC 29201, US
LAF English
LA English
DT Patent
PI WO 2003059271 A2 20030724
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2003-US1099 A 20030114
PRAI US 2002-60/348,298 20020114
US 2003-10/341,174 20030113

L20 ANSWER 9 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS
TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP
ABEN Compounds of the formula (I), wherein R<sb>1</sb>, R<sb>1</sb>-R<sb>7</sb>and alk have meaning as defined, pharmaceutical compositions thereof, and use thereof for the treatment and/or prevention of cardiovascular disorders responsive to ACE and NEP inhibition and/or ECE inhibition.
ABFR L'invention concerne des composes de formule (I), dans laquelle R<sb>1</sb>, R<sb>1</sb>-R<sb>7</sb> et alk ont les designations specifiees, ainsi que des compositions pharmaceutiques de ces produits et l'utilisation de celles-ci pour le traitement et/ou la prevention de maladies cardiovasculaires sensibles a l'inhibition de ACE et NEP et/ou a l'inhibition de ECE.
AN 2003027091 PCTFULL ED 20030410 EW 200314
TIEN PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS
TIFR DERIVES DU PYRANNE UTILISES COMME INHIBITEURS DE ACE ET NEP
IN FINK, Cynthia, Anne, 1 Kensington Court, Lebanon, NJ 08833, US [US, US]
PA NOVARTIS AG, Lichtstrasse 35, CH-4056 Basel, CH [CH, CH], for all designates States except AT US; NOVARTIS PHARMA GMBH, Brunner Strasse 59, A-1235 Vienna, AT [AT, AT], for AT only; FINK, Cynthia, Anne, 1 Kensington Court, Lebanon, NJ 08833, US [US, US], for US only
AG GROS, Florent, Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel, CH
LAF English

LA English
DT Patent
PI WO 2003027091 A1 20030403
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LT LU LV MA MD MK MN MX NO NZ OM PH PL PT RO RU SE SG SI SK TJ TM TN TR TT UA US UZ VC VN YU ZA ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR
AI WO 2002-EP10608 A 20020920
PRAI US 2001-60/323,825 20010921

L20 ANSWER 10 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
TIFR CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISES POUR PPAR
ABEN This invention provides new chemical entities useful for treating a variety of clinical disorders including those that are influenced by the activity of peroxisome proliferator activated receptors (PPAR) including PPARalpha, PPARdelta, and or PPARgamma. The structures of the compounds and methods to design, make and use the compounds are provided. Tautomers, stereoisomers and derivatives of the subject compounds, and pharmaceutically acceptable salts and solvates thereof, and their uses in the treatment of metabolic, inflammatory, autoimmune, proliferative and degenerative diseases are also provided.
ABFR L'invention concerne des entites chimiques utiles dans le traitement de troubles cliniques varies y compris de ceux qui sont influences par l'activite de recepteurs actives du proliferateur de peroxysome (PPAR) incluant PPARalpha, PPARdelta, et/ou PPARgamma. Elle concerne aussi les structures de ces composes, et les procedes de conception, de fabrication et d'utilisation de ces composes. Elle concerne enfin des tautomeres, des stereoisomeres et des derives de ces composes, ainsi que des sels et des solvates de ces composes, acceptables sur le plan pharmaceutique, et leurs utilisations dans le traitement de maladies metaboliques, inflammatoires, auto-immunes, proliferatives et degeneratives.
AN 2002076177 PCTFULL ED 20021011 EW 200240
TIEN DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
TIFR CONCEPTION ET SYNTHESE DE LIGANDS OPTIMISES POUR PPAR
IN PERSHADSINGH, Harrihar, Ajodhya, 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US];
AVERY, Mitchell, Allen, 303 Woodland Hills Drive, Oxford, MS38655, US [US, US]
PA BETHESDA PHARMACEUTICALS, INC., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US], for all designates States except US;
PERSHADSINGH, Harrihar, Ajodhya, 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US], for US only;
AVERY, Mitchell, Allen, 303 Woodland Hills Drive, Oxford, MS38655, US [US, US], for US only
AG JOHNSTON, Madeline, I., Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018, US
LAF English
LA English
DT Patent
PI WO 2002076177 A2 20021003
DS W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW
RW (ARIPO): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
AI WO 2002-US9287 A 20020325
PRAI US 2001-60/278,097 20010323
US 2001-60/283,774 20010413

L20 ANSWER 12 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
ABEN The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatological, cardiovascular immunological, neurological, ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human or an animal in need thereof a therapeutic amount of pharmacological compositions comprising a pharmaceutically acceptable carrier, and a PPARγ agonist which cross-activates PPARα or PPARδ or both, or a PPARγ partial agonist, or a PPARγ/RXR agonist, effective to reverse, slow, stop, or prevent the pathological inflammatory or degenerative process.
ABFR L'invention concerne des procedes d'utilisation de ligands PPAR dans le traitement de maladies inflammatoires endocrines, dermatologiques, cardio-vasculaires, immunologiques, neurologiques, ophtalmiques, neoplasiques, pulmonaires, et de dysfonctionnements lies a l'age. L'invention concerne de plus des methodes de traitement de ces etats et maladies, qui comprennent l'etape consistant a administrer a un etre humain ou a un animal necessitant un tel traitement une quantite therapeutique de compositions pharmacologiques contenant un excipient pharmaceutiquement acceptable et un agoniste de PPARγ qui active par reaction croisee PPARα et/ou PPARδ, ou un agoniste partiel de PPARγ, ou un agoniste de PPARγ/RXR permettant d'inverser, de ralentir, d'arreter ou de prevenir le processus inflammatoire ou degeneratif.
AN 2002013812 PCTFULL ED 20020711 EW 200208
TIEN METHODS FOR TREATING INFLAMMATORY DISEASES
TIFR TRAITEMENTS DE MALADIES INFLAMMATOIRES
IN PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
PA PERSHADSINGH, Harrihar, A., 404 Windsor Park Drive, Bakersfield, CA 93311, US [US, US]
LAF English
LA English
DT Patent
PI WO 2002013812 A1 20020221
DS W: AU CA MX NZ US
RW (EPO): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR
AI WO 2001-US25668 A 20010816
PRAI US 2000-60/225,907 20000817
US 2000-60/230,509 20000906

L20 ANSWER 13 OF 14 PCTFULL COPYRIGHT 2006 Univentio on STN
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
ABEN The present invention relates to methods and compositions for treating Alzheimer's disease and
other diseases and conditions with an inflammatory component (e.g., central nervous system injury).
In particular, the present invention provides agents that regulate the production of proinflammatory
and neurotoxic products involved in Alzheimer's disease and other diseases and conditions with an
inflammatory component.
ABFR La presente invention concerne des methodes et des compositions de

traitement de la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante
inflammatoire (par exemple, des
lesions au systeme nerveux central). En particulier, la presente
invention concerne des agents
regulant la production de produits pro-inflammatoires et neurotoxiques
appliques dans la maladie
d'Alzheimer ainsi que d'autres maladies et etats a composante
inflammatoire.

AN 2000032190 PCTFULL ED 20020515
TIEN COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, CENTRAL NERVOUS SYSTEM INJURY, AND INFLAMMATORY DISEASES
TIFR COMPOSITIONS ET METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER, DE LESIONS DU SYSTEME NERVEUX CENTRAL ET DE MALADIES INFLAMMATOIRES
IN LANDRETH, Gary;
COMBS, Colin;
SILVER, Jerry;
FITCH, Michael, T.
PA CASE WESTERN RESERVE UNIVERSITY
LA English
DT Patent
PI WO 2000032190 A1 20000608
DS W: AU CA IL JP KR AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE
AI WO 1999-US27987 A 19991124
PRAI US 1998-09/200,700 19981127

=> d his

(FILE 'HOME' ENTERED AT 12:59:47 ON 05 SEP 2006)

FILE 'REGISTRY' ENTERED AT 12:59:55 ON 05 SEP 2006
L1 STRUCTURE UPLOADED
L2 7 S L1
L3 96 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:03:21 ON 05 SEP 2006
L4 56 S L3
L5 1 S L4 AND (ASTHMA OR ALLERGY OR HYPERSENSITIVITY)
L6 38 S L3/THU
L7 17 S L6 AND PPAR
L8 3 S L7 AND (ASTHMA OR ALLERGY OR INFLAMMATION)
L9 5 S L6 AND (ASTHMA OR ALLERGY OR INFLAMMATION)

FILE 'REGISTRY' ENTERED AT 13:08:11 ON 05 SEP 2006
SEL L2
SEL L3

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:08:54 ON 05 SEP 2006
SEA CIGLITAZONE AND ASTHMA

1	FILE AGRICOLA
1	FILE BIOENG
5	FILE BIOSIS
1	FILE BIOTECHABS
1	FILE BIOTECHDS
1	FILE CABA
12	FILE CAPLUS
5	FILE DDFU
5	FILE DRUGU

```
              12   FILE EMBASE
               6   FILE ESBIOBASE
               4   FILE IFIPAT
               1   FILE LIFESCI
               7   FILE MEDLINE
               4   FILE PASCAL
               9   FILE SCISEARCH
               1   FILE TOXCENTER
             390   FILE USPATFULL
              62   FILE USPAT2
               5   FILE WPIDS
               1   FILE WPIFV
               5   FILE WPINDEX
              24   FILE EPFULL
             101   FILE IMSPATENTS
               1   FILE INPADOC
               1   FILE PATDPAFULL
             259   FILE PCTFULL
L10             QUE CIGLITAZONE AND ASTHMA
                ---------

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:10:25 ON 05 SEP 2006
L11          649 S CIGLITAZONE AND ASTHMA
L12          203 S L11 AND PPAR

     FILE 'EMBASE, CAPLUS' ENTERED AT 13:11:28 ON 05 SEP 2006
L13           24 S CIGLITAZONE AND ASTHMA
L14           18 S L13 AND PPAR
L15           14 DUP REM L14 (4 DUPLICATES REMOVED)
L16            0 S L14 NOT PY>2002

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:12:16 ON 05 SEP 2006
L17           18 S L12 NOT PY>2002

     INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
     AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
     CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
     DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:13:57 ON 05 SEP 2006
                SEA (E9-E111) AND ASTHMA
                ---------
                1   FILE CAPLUS
                1   FILE IFIPAT
               21   FILE USPATFULL
                2   FILE USPAT2
                1   FILE WPIDS
                1   FILE WPINDEX
               22   FILE PCTFULL
L18             QUE (("AD 4995"/BI OR "AD 5075"/BI OR "AD 5079"/BI OR "AD 5080"
                ---------

     FILE 'USPATFULL, PCTFULL' ENTERED AT 13:18:11 ON 05 SEP 2006
L19           43 S (E9-E111) AND ASTHMA
L20           14 S L19 NOT PY>2003
```